| Ipratropium Viatris | 🇳🇿Nueva Zelanda | | Nebuliser soln 250 mcg per ml, 2 ml ampoule | Financiado | |
| Ipratropium Viatris | 🇳🇿Nueva Zelanda | | Nebuliser soln, 250 mcg per ml, 2 ml ampoule | Financiado | |
| Atrovent | 🇳🇿Nueva Zelanda | | Aerosol inhaler, 20 mcg per dose CFC-free | Financiado | |
| CombiprasalCombinación | 🇳🇿Nueva Zelanda | | Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule | Financiado | |
| CombiprasalCombinación | 🇳🇿Nueva Zelanda | | Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule | Financiado | |
| Accord | 🇳🇿Nueva Zelanda | | Nebuliser soln, 250 mcg per ml, 2 ml ampoule | Financiado | |
| Accord | 🇳🇿Nueva Zelanda | | Nebuliser soln 250 mcg per ml, 2 ml ampoule | Financiado | |
| AnyCombinación | 🇳🇿Nueva Zelanda | | Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose | Financiado | |
| Any | 🇳🇿Nueva Zelanda | | Nebuliser soln 250 mcg per ml, 1 ml ampoule | Financiado | |
| Any | 🇳🇿Nueva Zelanda | | Aerosol inhaler 20 mcg per dose | Financiado | |
| CiplaCombinación | 🇳🇿Nueva Zelanda | | Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 3 ml vial | Financiado | |
| CiplaCombinación | 🇳🇿Nueva Zelanda | | Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 3.0 ml vial | Financiado | |
| DuolinCombinación | 🇳🇿Nueva Zelanda | | Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule | Financiado | |
| DuolinCombinación | 🇳🇿Nueva Zelanda | | Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml ampoule | Financiado | |
| Duolin HFACombinación | 🇳🇿Nueva Zelanda | | Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg per dose CFC-free | Financiado | |
| Univent | 🇳🇿Nueva Zelanda | | Nebuliser soln, 250 mcg per ml, 2 ml ampoule | Financiado | |
| Univent | 🇳🇿Nueva Zelanda | | Nebuliser soln 250 mcg per ml, 2 ml ampoule | Financiado | |
| Univent | 🇳🇿Nueva Zelanda | | Aqueous nasal spray, 0.03% | Financiado | |
| Univent | 🇳🇿Nueva Zelanda | | Aqueous nasal spray 0.03% | Financiado | |
